358 related articles for article (PubMed ID: 11148445)
1. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.
Vecchi M; Meucci G; Gionchetti P; Beltrami M; Di Maurizio P; Beretta L; Ganio E; Usai P; Campieri M; Fornaciari G; de Franchis R
Aliment Pharmacol Ther; 2001 Feb; 15(2):251-6. PubMed ID: 11148445
[TBL] [Abstract][Full Text] [Related]
2. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
[TBL] [Abstract][Full Text] [Related]
3. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study.
Pokrotnieks J; Marlicz K; Paradowski L; Margus B; Zaborowski P; Greinwald R
Aliment Pharmacol Ther; 2000 Sep; 14(9):1191-8. PubMed ID: 10971236
[TBL] [Abstract][Full Text] [Related]
5. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Kruis W; Kiudelis G; Rácz I; Gorelov IA; Pokrotnieks J; Horynski M; Batovsky M; Kykal J; Boehm S; Greinwald R; Mueller R;
Gut; 2009 Feb; 58(2):233-40. PubMed ID: 18832520
[TBL] [Abstract][Full Text] [Related]
6. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
[TBL] [Abstract][Full Text] [Related]
7. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial.
Paoluzi P; D'Albasio G; Pera A; Bianchi Porro G; Paoluzi OA; Pica R; Cottone M; Miglioli M; Prantera C; Sturniolo G; Ardizzone S
Dig Liver Dis; 2002 Nov; 34(11):787-93. PubMed ID: 12546514
[TBL] [Abstract][Full Text] [Related]
8. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial.
Gionchetti P; Ardizzone S; Benvenuti ME; Bianchi Porro G; Biasco G; Cesari P; D'albasio G; De Franchis R; Monteleone G; Pallone F; Ranzi T; Trallori G; Valpiani D; Vecchi M; Campieri M
Aliment Pharmacol Ther; 1999 Mar; 13(3):381-8. PubMed ID: 10102972
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis.
Gibson PR; Fixa B; Pekárková B; Bátovský M; Radford-Smith G; Tibitanzl J; Gabalec L; Florin TH; Greinwald R
Aliment Pharmacol Ther; 2006 Apr; 23(7):1017-26. PubMed ID: 16573804
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
Miner PB; Wedel MK; Xia S; Baker BF
Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
[TBL] [Abstract][Full Text] [Related]
11. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882
[TBL] [Abstract][Full Text] [Related]
12. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M
Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857
[TBL] [Abstract][Full Text] [Related]
13. Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis.
Connolly MP; Poole CD; Currie CJ; Marteau P; Nielsen SK
Digestion; 2009; 80(4):241-6. PubMed ID: 19828955
[TBL] [Abstract][Full Text] [Related]
14. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
[TBL] [Abstract][Full Text] [Related]
15. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
Kruis W; Brandes JW; Schreiber S; Theuer D; Krakamp B; Schütz E; Otto P; Lorenz-Mayer H; Ewe K; Judmaier G
Aliment Pharmacol Ther; 1998 Aug; 12(8):707-15. PubMed ID: 9726382
[TBL] [Abstract][Full Text] [Related]
16. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
Raedler A; Behrens C; Bias P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
18. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
19. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
[TBL] [Abstract][Full Text] [Related]
20. Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study.
Watanabe M; Hanai H; Nishino H; Yokoyama T; Terada T; Suzuki Y
Inflamm Bowel Dis; 2013 Jul; 19(8):1681-90. PubMed ID: 23624890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]